Patent ID: 7109329

Claim:
Pharmacologically active compositions having the capability of improving the neurological health of a mammal, the compositions comprising a unit dosage amount of a guanidino compound having at least two neurologically active receptor groups, one such neurologically active receptor group providing alpha-adrenergic agonist activity and a second such neurologically active receptor group providing dopaminergic agonist activity, the alpha-adrenergic agonist activity further being provided by at least one guanidino group and the dopaminergic agonist activity being provided by at least one 3,4-disubstituted phenyl group, each such phenyl substituent being negatively charged and being selected from the group consisting of hydroxyl groups and halogen atoms, and the guanidino compound being sufficiently lipophilic to be capable of crossing the blood/central nervous system barrier, and a physiologically suitable carrier, wherein the the guanidino compound is selected from the group consisting of: 2-(Amino)-4-(2,6-dichlorobenzylideneamino)-6-(3,4-dihydroxyphenyl-7-(S)-hydroxyethyleneamino)1,3,5-s-Triazine; 2,4-Bis-(2,6-dichlorobenzylideneamino)-6-(3,4-dihydroxyphenylethylamino)-1,3,5-s-triazine; 2-(2,6-Dichlorobenzylideneamino)-4-(3,4-dihydroxyphenylethylamino)-6-(5-hydroxyindole-ethylamino)-1,3,5-s-triazine; N-(2,6-Dichlorobenzylideneguanidino)-2-(3,4-dihydroxyphenyl)-2-(S)-hydroxyethylimine; 3,4-Dihydroxyphenylethylene aminoguanidine; 3-(3,4-Dichlorophenoxy)-benzylidene aminoguanidine; 3,4-Dichlorophenylethylaminoguanidine; N-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-carbonyl)N′-(3,4-dihydroxyphenyl)-2-(S)-hydroxyethylguanidine; and 3-(3,4-Dihydroxyphenyl)-2-(S)-(2,6-dichlorbenzylideneamino)-N-guanidinopropionamide.